MRP4/ABCC4-mediated cAMP extrusion as a new potential target for cancer therapy

DAVIO CARLOS

Mar del Plata

Simposio; - SAIB - 51 Annual Meeting Argentine Society for Biochemistry and Molecular Biology; 2015

SAIB

MRP4/ABCC4-mediated cAMP extrusion as a new potential target for cancer therapyProf. Dr. Carlos Davio. ININFA (UBA-CONICET) y Cátedra de Química Medicinal (FFYB, UBA). Buenos Aires, Argentina.G-protein coupled receptors (GPCRs) are the major membrane receptors that mediate extracellular signal transduction. These key signaling mediators are targeted by 25% of the therapeutic agents currently used in clinical treatments. Although diverse extracellular signals activate GPCRs leading to an increase in cAMP, signal specificity results from accurate adjustments at different levels of the cAMP dependent pathway. Cyclic AMP was the first second messenger reported and since then numerous studies have shown its participation in many physiological and/or pathophysiological processes. Cancer is one of the main causes of death worldwide and most of the drugs used in cancer therapy are highly toxic and/or lack specificity. In this context searching for novel specific targets to define new therapeutic strategies is crucial. Our results, provide solid evidence as to propose MRP4-mediated cAMP extrusion as a new target for cancer therapy. In the present lecture the paradigmatic second messenger cAMP and its complex signal transduction network will be addressed with the aim to define therapeutic targets for the development of safer and more efficacious drugs to be used in cancer clinical therapies. Current knowledge is challenging the main actors of the Signal Transduction Play, starring cAMP. Unknown actors emerge as potential main characters with a promising future on stage.